Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Products under Development by Stage of Development | 10 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Products under Development by Therapy Area | 11 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Products under Development by Indication | 12 | 2 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Products under Development by Companies | 17 | 3 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Products under Development by Universities/Institutes | 20 | 3 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Therapeutics Assessment | 23 | 6 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Companies Involved in Therapeutics Development | 29 | 9 |
| BioApex, s.r.o. | 29 | 1 |
| C4X Discovery Holdings PLC | 30 | 1 |
| Catabasis Pharmaceuticals, Inc. | 31 | 1 |
| Evgen Pharma Plc | 32 | 1 |
| Ixchel Pharma, LLC | 33 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 34 | 1 |
| Reata Pharmaceuticals, Inc. | 35 | 1 |
| Rigel Pharmaceuticals, Inc. | 36 | 1 |
| XenoPort, Inc. | 37 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drug Profiles | 38 | 40 |
| BA-1521 Drug Profile | 38 | 1 |
| bardoxolone methyl Drug Profile | 39 | 5 |
| CAT-4001 Drug Profile | 44 | 1 |
| dimethyl fumarate DR Drug Profile | 45 | 4 |
| IXC-101 Drug Profile | 49 | 1 |
| IXC-103 Drug Profile | 50 | 1 |
| LH-503 Drug Profile | 51 | 1 |
| LH-526 Drug Profile | 52 | 1 |
| MG-132 Drug Profile | 53 | 1 |
| MIND-4 Drug Profile | 54 | 1 |
| monosodium luminol Drug Profile | 55 | 2 |
| omaveloxolone Drug Profile | 57 | 3 |
| R-970 Drug Profile | 60 | 1 |
| SFX-02 Drug Profile | 61 | 1 |
| SFX-03 Drug Profile | 62 | 1 |
| Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology Drug Profile | 63 | 1 |
| Small Molecule to Activate Nrf2 for Inflammation Drug Profile | 64 | 1 |
| Small Molecules to Activate NRF-2 for COPD and Multiple Sclerosis Drug Profile | 65 | 1 |
| Small Molecules to Activate Nrf2 for Cancer and Inflammation Drug Profile | 66 | 1 |
| Small Molecules to Activate Nrf2 for Inflammation Drug Profile | 67 | 1 |
| Small Molecules to Activate Nrf2 for Oncology and Inflammation Drug Profile | 68 | 1 |
| Sulforadex Drug Profile | 69 | 2 |
| TBE-31 Drug Profile | 71 | 1 |
| trigonelline hydrochloride Drug Profile | 72 | 1 |
| VEDA-1209 Drug Profile | 73 | 1 |
| XP-23829 Drug Profile | 74 | 4 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Dormant Projects | 78 | 5 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Discontinued Products | 83 | 1 |
| Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Featured News &Press Releases | 84 | 18 |
| Jul 05, 2016: Bach Pharma Appoints Kelly Blackburn as Chief Executive Officer | 84 | 1 |
| Jun 23, 2016: Reata Pharmaceuticals Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension | 84 | 1 |
| May 03, 2016: Evgen Pharma: First Patient Dosed in Phase II Clinical Trial in SAH | 85 | 1 |
| Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness | 85 | 3 |
| Apr 12, 2016: Biogen to Present Data on TECFIDERA at 2016 AAN Annual Meeting | 88 | 1 |
| Mar 02, 2016: Approval of Phase II Clinical Trial in SAH | 89 | 1 |
| Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich s Ataxia | 90 | 1 |
| Jan 05, 2016: Reata Enrolls First Patient with Pulmonary Hypertension Associated with Interstitial Lung Disease in LARIAT, a Phase 2 Study Examining Bardoxolone Methyl for the Treatment of Patients with Pulmonary Hypertension | 90 | 1 |
| Oct 27, 2015: Reata Announces Initial Phase 2 Pulmonary Arterial Hypertension Data for Bardoxolone Methyl and Planned Initiation of Phase 3 Study | 91 | 2 |
| Oct 23, 2015: Updated recommendations to minimize the risk of the rare brain infection PML with Tecfidera | 93 | 2 |
| Oct 07, 2015: New Data Show Strong, Sustained Effects of TECFIDERA in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients | 95 | 3 |
| Oct 01, 2015: Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, On New TECFIDERA Data Demonstrating Importance of Early Treatment | 98 | 1 |
| Sep 16, 2015: Reata to Present Initial Phase 2 Data on Bardoxolone Methyl, a Novel Experimental Therapy for Pulmonary Hypertension Used in Patients on Stable Background PAH Therapy | 99 | 1 |
| Sep 15, 2015: XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis | 99 | 2 |
| Sep 02, 2015: USPTO Dismisses Inter Partes Review Petition of Biogen s Patent 514 for TECFIDERA (Dimethyl Fumarate) | 101 | 1 |
| Appendix | 102 | 2 |
| Methodology | 102 | 1 |
| Coverage | 102 | 1 |
| Secondary Research | 102 | 1 |
| Primary Research | 102 | 1 |
| Expert Panel Validation | 102 | 1 |
| Contact Us | 102 | 1 |
| Disclaimer | 103 | 1 |
